IDEXX Laboratories Receivables 2010-2024 | IDXX

IDEXX Laboratories receivables for the quarter ending September 30, 2024 were $0.511B, a 12.93% increase year-over-year.

  • IDEXX Laboratories receivables for 2023 were $0.457B, a 14.18% increase from 2022.
  • IDEXX Laboratories receivables for 2022 were $0.401B, a 8.76% increase from 2021.
  • IDEXX Laboratories receivables for 2021 were $0.368B, a 11.14% increase from 2020.

IDEXX Laboratories Receivables 2010-2024 | IDXX

  • IDEXX Laboratories receivables for 2023 were $0.457B, a 14.18% increase from 2022.
  • IDEXX Laboratories receivables for 2022 were $0.401B, a 8.76% increase from 2021.
  • IDEXX Laboratories receivables for 2021 were $0.368B, a 11.14% increase from 2020.
Related Stocks
Company NameMarket
Cap
Thermo Fisher Scientific (TMO)$194.7B
Intuitive Surgical (ISRG)$191.9B
Alcon (ALC)$42.1B
Edwards Lifesciences (EW)$41.4B
IQVIA Holdings (IQV)$34.7B
DexCom (DXCM)$29.2B
STERIS (STE)$20.9B
Waters (WAT)$20.5B
SONOVA HOLDING (SONVY)$20.3B
Hologic (HOLX)$18.2B
Fresenius Medical Care AG KGaA (FMS)$13B
Sysmex ADR (SSMXY)$12.7B
Globus Medical (GMED)$11.3B
Penumbra (PEN)$9.1B
Teleflex (TFX)$9B
Masimo (MASI)$8.8B
Glaukos (GKOS)$8B
PROCEPT BioRobotics (PRCT)$4.9B
Integer Holdings (ITGR)$4.5B
Veracyte (VCYT)$3B
Inari Medical (NARI)$3B
LivaNova (LIVN)$2.8B
TransMedics (TMDX)$2.8B
Nihon Kohden (NHNKY)$2.3B
Elekta AB (EKTAY)$2.2B
Tandem Diabetes Care (TNDM)$1.8B
RxSight (RXST)$1.8B
Integra LifeSciences Holdings (IART)$1.8B
Alphatec Holdings (ATEC)$1.4B
Artivion (AORT)$1.1B